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Pharmacokinetic analysis and tissue distribution of Vam3 2551. Introduction
More than 400 new naturally occurring stilbenes have been
isolated and identiﬁed from January 1995 to now1. Stilbenes are
of particular interest to chemists because of their range of
biological activities2. Resveratrol, the most representative com-
pound, has been associated with several biological activities such
as anti-oxidant, anti-inﬂammatory, analgesic, cardio-protective,
neuro-protective, chemo-preventive, anti-ageing and antimicrobial
activities3–5. In recent years some stilbene oligomers, especially
resveratrol oligomers, have attracted attention because of their wider
range of biological activities compared with the monomer6–8.
However, studies on resveratrol oligomers are limited to some
preliminary pharmacological research at present.
Vam3 (Amurensin H), a resveratrol dimer, was isolated from
ethanol extracts of Vitis amurensis Rupr (Fig. 1). V. amurensis
Rupr, belonging to a family of Vitaceae, grows in the northeast
and central parts of China. The roots and stems have been used in
traditional Chinese medicines for many years. Some mature
synthetic routes for Vam3 have been achieved, too9. Previous
in vivo and in vitro studies have found that Vam3 had anti-
asthmatic10–12 and anti-chronic obstructive pulmonary disease
(COPD) effects13,14. COPD is characterized by progressive,
partially reversible airﬂow obstruction associated with abnormal
airway inﬂammation and oxidant/antioxidant imbalance15, and
is predicted to become the third leading cause of mortality by
203016. Vam3 can inhibit autophagy in cigarette smoke conden-
sate (CS)–treated human bronchial epithelial cells and in CS-
exposed mouse lung by preventing mitochondrial dysfunction
and restoring the levels of SIRT1 and FOXO3a, which are
implicated in pulmonary emphysema in COPD. Some studies
have shown that resveratrol may be superior to other drugs for
COPD therapy17,18, yet research has shown that Vam3 was more
effective than resveratrol in inhibiting autophagy induced by CS13.
So far, no method has been published for the quantitation of
Vam3 in biological samples. The objective of this study was to
develop and validate a highly sensitive LC-MS/MS method for the
determination of Vam3 and to investigate its pharmacokinetic
properties in rat plasma and tissues.2. Experimental
2.1. Chemicals and materials
Vam3 (purity496.0%) was provided by the Institute of Materia
Medica of the Chinese Academy of Medical Sciences (Beijing,
China). Hesperetin, the internal standard (IS), was purchased from
Sigma (St. Louis, USA). LC–MS grade formic acid was purchased
from ROE Scientiﬁc Inc. (Newark, USA). HPLC grade acetonitrile
and methanol were purchased from ANPEL (Shanghai, China).Figure 1 Chemical structure of Vam3 and IS.Water was puriﬁed by a Milli-Q system from Millipore
(Billerica, USA).
2.2. Preparation of calibration and quality control samples
Stock solutions were prepared by dissolving Vam3 and IS in
methanol to obtain 0.2 mg/mL for each. A series of working
standard solutions were prepared by diluting the Vam3 stock
solution with methanol to concentrations of 16.4–10,000 ng/mL.
The IS stock solution was diluted with methanol to a ﬁnal
concentration of 200 ng/mL. All solutions were stored at –20 1C
before use.
Calibration curves and quality control (QC) samples were
prepared by adding Vam3 working standard solutions into
100 μL of blank rat plasma or tissue homogenate. Calibration
curves were prepared at concentrations of 1.64, 4.10, 10.24, 25.6,
64, 160, 400, 1000 ng/mL for plasma, heart, liver, lung, kidney
and small intestine. QC samples of Vam3 were prepared at four
different levels in rat plasma or tissue homogenate at concentra-
tions of 1.64, 4.10, 400 and 800 ng/mL (namely LLOQ, LQC,
MQC and HQC). Standard calibration samples and QC samples
were stored at 20 1C until analysis.
2.3. Sample preparation and extraction
An aliquot of 100 μL of each plasma or tissue homogenates
sample was mixed with 20 μL of working IS solution (200 ng/mL).
The mixture was vortexed for 30 s and then ethyl acetic
(800 μL) was added for extraction. After vortexing for 3 min
and centrifugation at 10,000 g for 15 min, 750 μL of the
supernate was transferred to a new tube and evaporated to dryness
at 40 1C under a gentle stream of nitrogen. The residue was then
reconstituted in 200 μL methanol. After centrifugation at 10,000
g for 15 min, 10 μL of the supernate was injected for LC-MS/MS
analysis.
2.4. LC-MS/MS method
The LC-MS/MS system consisted of a Shimadzu LC-20AD
UPLC system and an Applied Biosystems Sciex Qtrap5500
(MDS-Sciex, Concord, Canada). A shim-pack XR-ODS column
(2.3 mm  75 mm, 3 μm, Shimadzu, Tokyo, Japan) was used for
separation. The mobile phase was composed of A (0.1% formic
acid–water, v/v) and B (acetonitrile). The column temperature was
maintained at 40 1C and the injection volume was 10 μL. The
optimal gradient elution condition for plasma, heart, liver, lung
and kidney was as follows: 0–0.03 min, 50% B; 0.03–0.3 min,
50%–75% B; 0.3–1.8 min, 75% B; 1.8–2.1 min 75%–50% B; 2.1–
6 min, 50% B, and the ﬂow rate was 0.2 mL/min.
The mass spectrometer was operated by electrospray ionization
in negative mode for analyte and IS. The typical MS/MS spectra
for Vam3 and IS are shown in Fig. 2. Quantiﬁcation was
performed using multiple reaction monitoring (MRM) mode of
the transitions m/z 451.0-345.0 for Vam3 with a declustering
potential (DP) of 180 V and m/z 301.0-164.0 for hesperetin
(IS) with a DP of 100 V, respectively. The dwell time was set at
200 ms per transition. The optimized collision energy (CE) and
collision exit potential were 32 eV and 10 eV, respectively.
The MS parameters were as follows: ion spray voltage: –4500 V;
temperature: 550 1C; nebulizer and turbo gases (nitrogen) were set
at 50 and 50 psi, respectively. The curtain gas using nitrogen was
Figure 2 The typical MS/MS spectrum for Vam3 (A) and IS (B).
Figure 3 Representative MRM chromatograms of (A) blank rat plasma,
proﬁles 1 h after oral administration of 70 mg/kg.
Ruixia Zhang et al.256set at 35 psi. Data acquisition and integration were performed
using the Analyst 1.5.1 software (Applied Biosystems, Foster
City, USA).2.5. Method validation
The LC-MS/MS method was validated in accordance with the
Guidance for Industry, Bioanalytical Method Validation of FDA.2.5.1. Selectivity
The selectivity was investigated by comparing blank plasma
samples and tissue homogenates from six individual rats with the
corresponding spiked plasma samples and tissue homogenates at the
LLOQ level of the analyte (Vam3 and IS) and actual samples.2.5.2. Linearity and LLOQ
The calibration curve was acquired by plotting the peak area ratio
of Vam3 to IS (Y) against the corresponding nominal Vam3
concentration (X) by weighted least-squares linear regression (1/X2
as a weighting factor). The LLOQ was deﬁned as the lowest
concentration of the calibration curve and produced a signal-to-
noise (S/N) ratio of 10. The acceptance criteria of accuracy and
precision were 715% deviation from the nominal value except
LLOQ, which was set at 720%.(B) rat plasma spiked with Vam3 at LLOQ, and (C) Vam3 in plasma
Figure 4 Representative MRM chromatograms of (A) blank lung tissue, (B) lung tissue spiked with Vam3 at LLOQ, and (C) Vam3 in lung
tissue proﬁles 1 h after oral administration of 70 mg/kg. The retention time for Vam3 and IS were 2.80 min and 3.10 min, respectively.
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The accuracy and precision were determined by analyzing the QC
samples of plasma, heart, liver, small intestine, kidney and lung at
four concentrations (n¼5 each) on three consecutive days. The
accuracy and precision were expressed in terms of relative error
(R.E.%) and relative standard deviation (R.S.D.%), respectively.
The intra- and inter-day precision should not exceed 15% and
accuracy should be within715% for the QC samples (LQC, MQC
and HQC), except for LLOQ, whose accuracy and precision
should be within 720%. The intra-day assay precision and
accuracy were estimated in the same day.2.5.4. Recovery and matrix effect
The extraction recovery was determined by comparing peak area
of Vam3 from spiked in blank matrix (plasma or tissue homo-
genate) with the peak area of analyte spiked in post-extracted
matrix at four QC concentrations (n¼5). The matrix effect was
evaluated at four QC concentrations (n¼5) by comparing the peak
areas of post-extraction plasma or tissue homogenate spiked with
analyte versus the standard solution of the analyte at corresponding
concentrations. The extraction recovery and matrix effect of IS
(200 ng/mL) also was investigated in a similar way. The precision
of extraction recovery or matrix effect should be no more than
15% (LQC, MQC and HQC), while for LLOQ it should not
exceed 20%.2.5.5. Stability
The stability of Vam3 in plasma and tissues homogenate was
investigated by analysis of four levels of QC samples stored at
20 1C for one month (long-term stability), at room temperature
for 12 h (short-term stability) and after three freeze-thaw cycles.
Post-preparative stability was evaluated by analyzing the ready-to-
inject samples placed in an autosampler at room temperature for
24 h. The recovery stability was evaluated by 715% bias of the
actual value, except that the LLOQ level should not exceed 20%.
2.5.6. Dilution integrity
The levels of some plasma, liver and small intestine samples
exceeded the highest concentration of the calibration curve. To
investigate the effect of diluting over-range samples into the
calibration range, the accuracy and precision of dilution samples
at 20,000 ng/mL (plasma samples), 10,000 ng/mL (small intestine
homogenate) and 5000 ng/mL (liver homogenate) (each n¼5)
were assessed by performing a 20-fold dilution. The accuracy and
precision was required to be within the range of 715%.
2.6. Pharmacokinetic study and data analysis
Wistar rats (body weight 200720 g, 8 weeks) were purchased
from Beijing Military Medical Sciences Experimental Animal Co.,
Ltd. (Beijing, China). All animals were kept in an environmentally
controlled room. The room was maintained at a temperature of
Table 1 Intra-day and inter-day accuracy and precision of Vam3 (n¼5). a
Matrix Nominal concentration
(ng/mL)
Intra-day Inter-day
Measured concentration
(ng/mL)
Precision
R.S.D. (%)
Accuracy
R.E. (%)
Measured concentration
(ng/mL)
Precision
R.S.D. (%)
Accuracy
R.E. (%)
Plasma 1.64 1.56 9.3 –4.52 1.57 9.3 –4.19
4.10 3.91 8.7 –4.44 3.79 8.7 –7.57
400 398.80 7.5 –0.30 390.27 7.5 –2.43
800 761.80 5.0 –4.78 751.20 5.0 –6.10
Liver 1.64 1.56 9.3 –4.52 1.57 9.3 –4.19
4.10 4.12 9.1 0.54 4.13 8.4 0.94
400 392.80 5.0 –1.80 406.00 4.5 1.50
800 872.20 3.3 9.03 830.93 8.9 3.87
Heart 1.64 1.61 11.1 –1.83 1.59 9.6 –3.13
4 3.96 8.3 –3.37 3.92 5.7 –4.39
400 377.40 2.5 –5.65 395.07 7.6 –1.23
800 796.40 12.8 –0.45 764.73 8.4 –4.41
Kidney 1.64 1.63 8.2 –0.49 1.58 7.3 –3.58
4.10 4.47 6.2 9.08 4.37 5.1 6.64
400 410.00 6.7 2.50 418.00 4.5 4.50
800 795.40 3.4 –0.58 785.67 5.4 –1.79
Lung 1.64 1.63 8.5 –0.24 1.66 7.7 1.51
4.10 4.42 11.3 7.86 4.19 9.2 2.36
400 357.60 4.8 –10.60 388.13 7.3 –2.97
800 787.80 4.0 –1.53 795.07 4.6 –0.62
Small intestine 1.64 1.67 9.4 1.71 1.66 7.6 1.06
4.10 4.22 12.4 3.13 4.06 8.2 –0.96
400 378.20 4.1 –5.45 397.07 7.3 –0.73
800 754.80 7.7 –5.65 784.07 8.6 –1.99
aR.E. (%)¼(Measured concentration–Nominal concentration)/Nominal concentration 100.
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mately 12 h light/dark cycle.
Twelve Wistar rats (6 female, 6 male) were used for the
pharmacokinetic and bioavailability study. All rats had free access to
water and food. Diet was prohibited for 12 h before the experiment
while water was taken freely. All rats were randomly assigned to two
groups (n¼6) for intravenous or oral administration, respectively.
Blood samples (0.3 mL) were collected from the ocular vein into
1.5 mL Eppendorf tubes at 0.25, 0.5, 1, 1.5, 2, 2.25, 2.5, 3, 4, 6, 8 and
12 h after oral (singe dosage, 70 mg/kg) administration of Vam3.
Similarly, 0.3 mL blood samples were collected from the ocular vein
into 1.5 mL Eppendorf tubes at 0.033, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2,
4, 8 and 12 h after intravenous administration (singe dosage 2 mg/kg)
of Vam3. The samples were immediately centrifuged at 3000 g for
15 min. The plasma obtained (100 μL) was stored at 20 1C until
analysis.
The pharmacokinetic parameters of Vam3 were calculated by
DAS Software (version 3.2.4, China State Drug Administration)
using non-compartmental methods. Based on the calculated
AUC values, absolute bioavailability (F) was calculated as F%¼
(AUCp.o. dosei.v.)/(AUCi.v. dosep.o.) 100.
2.7. Tissue distribution study
Thirty Wistar rats (15 female, 15 male; weight 200720 g) were
randomly assigned to ﬁve groups (6 rats/group) to carry out a
tissue distribution study. Tissue samples, including the heart, liver,
lung, kidney and small intestine, were collected at 1, 2.5, 4, 6 and
12 h after oral administration (70 mg/kg). Tissue samples were
rinsed with 0.9% physiological saline solution to remove the bloodand blotted dry with ﬁlter paper. An accurately weighed amount of
the soft tissue samples (0.5 g) was individually homogenized with
normal saline (0.5 mL) and stored at 20 1C until analysis.3. Results and discussion
3.1. Method development
The ESI conditions for Vam3 and IS were optimized in both positive
and negative mode, but more stable and intense ions were observed in
negative mode. Protonated precursor [M – H]– ions at m/z 451.0 and
301.0 were obtained for Vam3 and IS respectively in Q1 full scan
mode. The most abundant ions in the product ion mass spectra were
345.0 and 164.0 for Vam3 and IS, respectively. The MRM transitions
of m/z 451.0-345.0 and m/z 301.0-164.0 were found for Vam3 and
IS, respectively. MS/MS operating conditions were optimized to obtain
the greatest intensity of the most abundant product ion by infusing the
standard solution (500 ng/mL) of analyte or IS into the ESI source via
a syringe pump.
Different mobile phases (methanol–water and acetonitrile–water
in various proportions) were tested during method development. It
was found that acetonitrile selected as the organic phase could
enhance the sensitivity in the negative ions mode and improve the
peak shape. Both Vam3 and IS have higher response signals and
decreased tailing of the chromatographic peak when 0.1% formic
acid was added in. Reduction in the proportion of organic phase
enhanced the sensitivity of analyte, but the retention time also was
extended. Finally, considering symmetrical peak shapes, good
resolution, and a short chromatographic run time, the gradient
Table 2 Recovery and matrix effect of Vam3 and IS in rat plasma and tissue homogenates (n¼5).
Compound Matrix Nominal concentration (ng/mL) Extraction recoverya (%) R.S.D. (%) Matrix effectb (%) R.S.D. (%)
Vam3 Plasma 1.64 66.1 7.6 81.4 4.7
4 66.0 11.8 80.2 11.2
400 64.5 9.4 81.6 7.7
800 66.1 10.3 79.1 11.8
Liver 1.64 62.2 19.6 107.1 2.5
4 61.6 13.7 93.1 10.4
400 59.3 6.1 93.0 3.2
800 57.4 6.5 91.7 4.3
Heart 1.64 60.7 12.7 96.7 10.5
4 59.2 14.7 93.1 10.4
400 59.3 6.1 91.1 3.2
800 57.9 6.6 89.2 4.3
Kidney 1.64 71.3 4.6 94.4 13.2
4 71.3 13.3 93.4 4.3
400 66.8 8.6 102.3 3.6
800 65.1 7.7 92.8 2.5
Lung 1.64 77.8 19.0 105.5 12.6
4 78.2 13.1 106.1 12.0
400 78.0 8.0 107.6 4.1
800 73.5 3.4 90.5 9.5
Small intestine 1.64 52.5 15.3 81.4 13.6
4 61.8 10.4 74.0 11.6
400 52.3 9.0 72.1 13.2
800 56.4 8.5 89.5 12.0
IS Plasma 20 68.4 7.2 78.5 5.3
Liver 20 64.9 10.3 91.8 11.7
Heart 20 66.4 9.1 88.7 3.6
Kidney 20 76.3 5.6 85.3 4.5
Lung 20 65.0 10.9 95.5 7.2
Small intestine 20 58.9 10.5 86.6 6.5
aExtraction recovery (%)¼Peak area of analyte spiked in blank matrix/Peak area of analyte spiked in post-extracted matrix 100.
bMatrix effect (%)¼Peak area of analyte spiked in post-extracted matrix/peak area of analyte spiked in solvent 100.
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(50:50, v/v) was selected, and the ﬂow rate was set at 0.2 mL/min.
The gradient mode proved to be stable according to method
validation results.
3.2. Sample preparation
Sample preparation by an efﬁcient extraction step is important in
determining Vam3 content in biological matrices. A protein
precipitation method was ﬁrst considered for the sample prepara-
tion for this work. Methanol and acetonitrile were used for protein
precipitation solution to investigate the matrix effect and extraction
recovery, respectively. But a serious ion suppression or matrix
effect for analyte was observed in the LC-MS/MS analyses, which
could not meet the requirements of the pharmacokinetic study.
Therefore, liquid-liquid extraction (LLE) was chosen to prepare
sample using ethyl acetate as extraction solvent. The results
indicated that it could provide satisfactory recovery and minimal
matrix effects for analyte and IS.
3.3. Selectivity and speciﬁcity
The assay condition provided adequate speciﬁcity for Vam3 and
IS analysis while no interfering peaks were observed. Typical
chromatograms of blank rat plasma, blank rat plasma spiked with
the analyte (at LLOQ level) and IS, and plasma sample at 1 h afteroral administration of Vam3 are shown in Fig. 3. The representa-
tive chromatograms acquired from blank lung tissue, blank lung
tissue spiked with the analyte (at LLOQ level) and IS, and lung
tissue sample at 1 h after oral administration of Vam3 are shown in
Fig. 4. The retention time of Vam3 and IS were 2.80 min and
3.10 min, respectively, in both plasma and tissue samples.
3.4. Calibration curve and LLOQ
For all matrices, calibration curves were determined from the peak
area ratio of Vam3 to IS (Y) against concentration (X) using 1/X2
weighting factor. The calibration curves were linear over the
following concentration ranges: 1.64–1000 ng/mL for plasma and
tissue samples. Typical regression equations for Vam3 in plasma
and each tissue are as follows: plasma, Y¼0.0117Xþ0.00521;
liver, Y¼0.00375Xþ0.00130; heart, Y¼0.00347Xþ0.00393; kid-
ney, Y¼0.00740Xþ0.0125; lung, Y¼0.00721Xþ0.0196; small
intestine, Y¼0.0122Xþ0.0150. The correlation coefﬁcients (r) were
greater than 0.99 for both analytes. The LLOQ of Vam3 was
1.64 ng/mL (S/N410) for all biological samples. Accuracy and
precision at LLOQ concentration did not exceed 720% R.S.D.
and R.E.
3.5. Intra- and inter-day precision and accuracy
Precision and accuracy were evaluated at four levels of QC samples
on three consecutive days. The results for intra- and inter-day precision
Table 3 Stability data of Vam3 in tissue and plasma. a
Matrix QC (ng/mL) Short-term (12 h) at room temperture Processed sample
(12 h at auto-sampler)
Three freeze-thaw cycles Long-term stability
R.S.D. (%) R.E. (%) R.S.D. (%) R.E. (%) R.S.D. (%) R.E. (%) R.S.D. (%) R.E. (%)
Plasma 4.10 2.3
0.59
3.8 –10.40 1.1 –7.23 13.7 –0.96
400 5.3
–7.83
7.4 2.25 0.2 –5.14 2.3 11.17
800 1.2
–5.71
1.8 –0.04 4.6 –0.92 3.2 9.00
Liver 4.10 4.0
–6.33
0.8 0.02 4.9 –9.97 2.8 7.42
400 5.3
0.08
1.7 –8.92 6.8 –5.36 4.5 2.00
800 6.1
–5.33
5.6 –6.42 1.6 –7.14 5.3 –1.50
Heart 4.10 7.8
–1.04
2.4 –4.54 1.3 –11.11 5.4 –7.55
400 3.3
11.33
1.4 –12.42 2.3 –2.89 9.2 2.92
800 1.2
–3.63
4.2 –2.33 6.1 –5.13 5.8 –1.88
Kidney 4.10 9.4
0.10
4.2 –0.07 2.2 –0.09 5.2 6.53
400 9.3
9.42
3.1 –8.25 6.5 3.81 3.6 6.33
800 6.7
–0.50
2.5 –8.88 3.3 4.97 7.4 7.33
Lung 4.10 5.2
0.10
3.6 5.71 4.7 4.82 6.2 –4.05
400 4.1
–0.08
6.3 –4.75 6.7 –6.33 2.7 2.00
800 4.8
–0.08
5.5 –4.83 2.0 –11.79 11.7 –2.88
Small intestine 4.10 2.4
0.10
1.7 –10.64 10.1 –2.75 4.5 –1.04
400 4.7
–3.50
4.0 8.08 5.3 6.00 7.0 7.25
800 4.2
5.00
8.0 –4.54 11.1 –1.50 0.9 –7.46
aR.E. (%)¼ (Measured concentration–Nominal concentration)/Nominal concentration 100.
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Figure 6 Vam3 concentrations (ng/g) in rat tissues 1, 2.5, 4, 6 and
12 h after oral administration of 70 mg/kg Vam3 (n¼6). Data are
means7SD.
Pharmacokinetic analysis and tissue distribution of Vam3 261and accuracy are presented in Table 1. The intra-day accuracies ranged
from –4.78% to –0.30% for plasma and from –10.60% to 9.08% for
tissue homogenates (heart, liver, lung, kidney and small intestine),
throughout the four QC concentrations examined. The intra-day
precision in R.S.D. varied by less than 12.8% for all rat bio-
samples. The data of the inter-day accuracy were within 7.57%
to 2.43% for plasma, 4.41% to –1.23% for heart, 4.19% to
3.87% for liver, 2.97% to 2.36% for lung, 3.58% to 6.64% for
kidney and –1.99% to 1.06% for small intestine, respectively, while
the inter-day precision varied by less than 9.6%. These results revealed
that the precision and accuracy of this assay were within the
acceptable range for the analysis of the rat bio-samples.
3.6. Extraction recovery and matrix effect
The extraction recoveries and matrix effects determined for Vam3
and IS are shown in Table 2. The extraction recoveries of Vam3 in
plasma at four QC concentrations (n¼5) were more than 64%.
The extraction recoveries of Vam3 in tissue samples were also
more than 52% at four QC concentrations (n¼5). The extraction
recovery rates of IS also exceeded 58% in the above samples. The
absolute matrix effect of Vam3 ranged from 79.1% to 81.6% in
plasma and from 72.1% to 107.6% in tissue samples, respectively.
The absolute matrix effect of IS at 200 ng/mL level ranged from
78.5% to 95.5% in the above biological matrixes. Valueso100%
indicated that there was ionization suppression for Vam3 and the
IS under the present conditions, but their values were similar and
kept consistent at the four QC concentrations. The relative matrixFigure 5 The mean plasma concentration-time proﬁle of Vam3 in rats af
of 2 mg/kg (B) Vam3 (n¼6). Data are means7SD.
Table 4 Non-compartmental pharmacokinetics parameters of Vam3
Parameter Unit
AUC(0–t) μg/L·h
AUC(0–1) μg/L·h
MRT(0–t) h
MRT(0–1) h
T1/2 h
Tmax h
V L/kg
CL L/h/kg
Cmax μg/L
Feffects expressed as R.S.D. (%) were acceptable witho13.6% for
Vam3 ando11.7% for IS. The above results conﬁrm that the
presence of matrix effects had practically no inﬂuence on the
determination of Vam3 in different rat matrices, and that the
present LC-MS/MS method is reliable.3.7. Stability and dilution
The stability tests were carried out under various conditions that
the samples might experience. In rat plasma and tissue homo-
genate, Vam3 was found to be stable for three freeze-thaw cycles,ter oral administration of 70 mg/kg (A) and intravenous administration
after a single oral and intravenous administration in rat plasma.
Mean7SD
Intravenous Oral
(2 mg/kg, n¼6) (70 mg/kg, n¼6)
2046.77315.0 565.17148.2
2059.47311.2 570.07150.3
0.470.2 4.470.8
0.5270.23 4.470.8
2.970.4 1.470.2
– 2.370.1
4.271.2 269.67100.8
1.070.2 130.9737.6
14460.072854.3 197.3741.4
– 0.79%
Table 5 Vam3 concentrations (ng/g) in rat tissues 12 h after two different administration methods (n¼6). Data are means7SD.
Time Concentrations of Vam3 (ng/g)
Lung Heart Kidney Liver Intestine
12 h (oral 70 mg/kg) 93.8744.6 13.379.6nn 11.176.2nn 127.6774.8 44.5718.6n
12 h (i.v. 2 mg/kg) 83.2749.8 4.572.9nn 1.6970.71nn 3.073.7nn 6.173.1nn
The signiﬁcance of the differences between groups was determined by one-way ANOVA.
nPo0.05 compared with lung.
nnPo0.01.
Ruixia Zhang et al.262at room temperature for 12 h, in the auto-sampler for 24 h and in a
long term freezer set at 20 1C for 30 days. As shown in Table 3,
that predicted concentrations for analyte at LQC, MQC and HQC
samples deviated within the assay variability limits (715%) of the
nominal concentration. In addition, dilution integrity experiments
were carried out with ﬁve replicates by a 20-fold dilution with
blank rat plasma, liver and small intestine. The results indicated
that the accuracy was within713.2% and the variation in precision
was less than 7.59%.3.8. Pharmacokinetic and tissue distribution studies
The assay method was applied in pharmacokinetic studies after
oral administration of 70 mg/kg or intravenous injection of
2 mg/kg Vam3 to rats (n¼6). The mean plasma concentration–
time curves are illustrated in Fig. 5, and the major pharmacokinetic
parameters of Vam3 from non-compartment model analysis are
presented in Table 4.
A relatively slow absorption, extensive distribution, as well as
quick elimination and clearance of Vam3 were indicated by the
pharmacokinetic parameters. After oral administration Vam3 at
70 mg/kg, the time to peak concentration (Tmax) was observed at
about 2.370.1 h, and peak plasma concentrations (Cmax) were
197.3741.4 μg/L. The mean area under the plasma concentration–
time curve from time zero to the last measurable plasma
concentration point (AUC0 t) and the mean area under the plasma
concentration–time curve from time zero to time inﬁnity
(AUC01) were 565.17148.2 and 570.07150.3 μg/L·h, respec-
tively. The apparent volume of distribution (V) value was
269.67100.8 L/kg for the oral group, suggesting that this
compound could extensively distribute into organs and tissues.
Clearance, MRT and T1/2 values were estimated at
130.9737.6 L/h/kg, 4.470.8 h and 1.470.2 h, respectively. That
indicated that Vam3 could be quickly eliminated from the
circulatory system. Low oral absolute bioavailability (0.79%) of
Vam3 was calculated after intravenous and oral administration. It
could be seen from the concentration-time curve that there were
double peaks (approximately at 4 h) of Vam3 after oral adminis-
tration in rat plasma. Because Vam3 has low bioavailability, data
points showed signiﬁcant variability, and enterohepatic circulation
might play a role. The homolog resveratrol has been reported to
undergo enterohepatic circulation which can result in a
concentration-time curve with two peaks19. However, the
double-peak feature of Vam3 needs further study.
The distribution of Vam3 in the various tissues, namely heart,
liver, lung, kidney and small intestine is listed in Fig. 6. After oral
administration of Vam3 at 70 mg/kg, results indicated that Vam3
was widely distributed in the tissues, and the concentration ofVam3 in certain tissues was much higher than that in the plasma.
The maximum concentration was observed at 2.5 h in all tissues
after oral administration. The highest tissue concentration of Vam3
was observed in the small intestine (2273.371187.3 ng Vam3/
tissue (g)), followed by the liver (1144.47667.5 ng/g), the kidney
(787.07259.8 ng/g), lung (404.07163.2 ng/g) and heart
(109.9790.2 ng/g). The data indicated that small intestine might
be the main absorption sites of Vam3. The dense blood vessel
network with high blood ﬂow may have relevance for the high
distribution of Vam3 in the liver and kidney. Twelve hours after
oral administration there was little in other tissue samples except
for lung and liver. Meanwhile, we also studied the distribution of
Vam3 in these tissues 12 h after intravenous administration. The
result (Table 5) showed that very little Vam3 could be detected in
other tissue samples beyond 12 h, but the concentration of Vam3
in the lung was 83.2749.8 ng/g. The level in lung remains
signiﬁcantly higher than in other tissues. Through cop analysis
for tissue by DAS Software using non-compartmental methods, we
found Vam3 had a relatively long terminal elimination half-life in
lung. It indicated that Vam3 may have certain afﬁnity for lung
tissue and provided the material basis for its pharmacological
actions in the treatment of COPD. However, the reasons for this
distribution proﬁle still need further investigation.4. Conclusions
A rapid and sensitive method by LC-MS/MS for the quantiﬁcation
of Vam3 was developed and validated in rat plasma and tissue.
The advantages of this method included short analysis time, high
sensitivity and simple sample preparation procedure. The pharma-
cokinetic data showed that Vam3 displayed negligible oral
bioavailability, but it had a relatively long terminal elimination
half-life in lung tissue following oral administration. The results
help us understand the pharmacological action of Vam3 for COPD
in vivo, even if its blood concentration is low. The reported
pharmacokinetic parameters of Vam3 in the present work will
provide helpful information for further development. How to
improve the oral bioavailability of Vam3 will be the focus in
further bio-pharmaceutics research.Acknowledgments
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